Exabis Library
Welcome to the e-CCO Library!
P331: Development of a novel transabdominal ultrasound disease activity score in patients with ulcerative colitis (UCUS score)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P331: Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P331: Real-world assessment of biological treatment of inflammatory bowel disease at an Austrian Referral Centre: the ULTIMATE study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P331: Risk Factors and Prediction Model for Fecal Incontinence in Patients with Crohn's Disease: A Multicenter Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P331: The safety of tioguanine exposure during pregnancy: a case series of seventy-three pregnancies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P332 Mindfulness-based stress reduction and cognitive intervention improve the health-related quality-of-life and ability to work in Crohn’s disease patients: A randomised controlled trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P332: A treat-to target strategy guided by pan-enteric valuation in paediatric Crohn’s disease improves outcomes at 2 years
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P332: External validation of intestinal ultrasound scores to detect endoscopic activity in children and adults with Crohn's disease: A prospective cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P332: Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P332: Influence of mesalamine maintenance therapy on progression of ulcerative proctitis in Korea
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P332: Multinational comparisons of practices in overseas travel in Crohn’s disease and ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P332: Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P332: Treat to target in Crohn's disease: ultrasonographic response is associated with better outcomes
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P333 Biologic longevity: Withdrawal of drugs due to remission is rare in clinical practice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P333: Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P333: Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P333: Early intestinal ultrasound remission is associated with endoscopic healing after one year of infliximab therapy in Crohn's disease: a multicentre prospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P333: Endoscopic severity and CRP predict failure of medical rescue therapy in patients with acute severe ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P333: Long-term efficacy and safety of thiopurines in patients with steroid-dependent ulcerative colitis: a retrospective investigation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P333: Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM